Detection of Early Glaucomatous Damage: Performance of Summary Statistics From Optical Coherence Tomography and Perimetry.
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
02 03 2022
02 03 2022
Historique:
entrez:
30
3
2022
pubmed:
31
3
2022
medline:
2
4
2022
Statut:
ppublish
Résumé
To evaluate the diagnostic performance of optical coherence tomography (OCT) and visual field (VF) summary statistics (metrics) that are available in OCT and VF reports. OCT disc and macular scans and 24-2 and 10-2 VFs were obtained from 56 healthy control (HC) eyes/participants and 61 eyes/patients with 24-2 mean deviation of better than -6 dB. All metrics were obtained from OCT radial, circle, and posterior pole cube scans and 24-2 and 10-2 VFs. Their diagnostic performances were evaluated, in isolation and in combinations. For specificity, the 56 HC eyes were used. For sensitivity, 40 of the 61 patient eyes were deemed likely glaucomatous based on an automated topographic method that evaluates structure-function (S-F) agreement. Any 1 of these 40 eyes not judged as abnormal by any given metric was considered a false negative. All single OCT and VF metrics misclassified HCs as glaucomatous and missed likely glaucomatous eyes. The best performing single metric was the temporal inferior thickness of the 3.5-mm circle scan, with 96% specificity and 83% sensitivity. Combinations of OCT-OCT and OCT-VF metrics markedly improved specificity. A newly proposed metric that evaluates structure-structure (S-S) agreement at a hemifield level had the highest accuracy. This S-S metric had 98% specificity and 80% sensitivity. OCT and VF metrics, single or in combinations, have only moderate sensitivity for eyes with early glaucoma. OCT and VF metrics combinations evaluating S-S or S-F agreement can be highly specific, which is an important implication for clinical and research purposes.
Identifiants
pubmed: 35353149
pii: 2778714
doi: 10.1167/tvst.11.3.36
pmc: PMC8976935
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
36Subventions
Organisme : NEI NIH HHS
ID : K99 EY032182
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY002115
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY025253
Pays : United States
Références
Prog Retin Eye Res. 2017 Mar;57:46-75
pubmed: 28012881
Annu Rev Vis Sci. 2021 Sep 15;7:693-726
pubmed: 34242054
Surv Ophthalmol. 2008 Nov;53 Suppl1:S17-32
pubmed: 19038620
J Glaucoma. 2006 Feb;15(1):40-6
pubmed: 16378017
Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):788-791
pubmed: 29392325
Br J Ophthalmol. 2014 Jul;98 Suppl 2:ii15-9
pubmed: 24357497
Arch Ophthalmol. 2005 Sep;123(9):1201-6
pubmed: 16157799
J Glaucoma. 2009 Mar;18(3):253-61
pubmed: 19295383
J Glaucoma. 2013 Dec;22(9):713-8
pubmed: 22668975
Invest Ophthalmol Vis Sci. 2007 Jan;48(1):244-50
pubmed: 17197539
Graefes Arch Clin Exp Ophthalmol. 2014 Feb;252(2):321-30
pubmed: 24337431
Br J Ophthalmol. 2014 Jul;98 Suppl 2:ii1-9
pubmed: 24934219
JAMA Ophthalmol. 2015 Jan;133(1):40-4
pubmed: 25256758
Am J Ophthalmol. 1989 Aug 15;108(2):130-5
pubmed: 2757094
Curr Opin Ophthalmol. 2016 Mar;27(2):102-10
pubmed: 26569530
Ophthalmology. 2018 Nov;125(11):1817-1827
pubmed: 30322450
Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1979 Jun 15;210(4):235-50
pubmed: 315173
Am J Ophthalmol. 2017 Feb;174:1-8
pubmed: 27818206
Am J Ophthalmol. 2018 Dec;196:10-17
pubmed: 30099037
Ophthalmology. 2015 Mar;122(3):502-10
pubmed: 25444638
Am J Ophthalmol. 2020 May;213:203-216
pubmed: 31899204
Arch Ophthalmol. 1992 Jun;110(6):812-9
pubmed: 1596230
Transl Vis Sci Technol. 2020 Oct 19;9(11):22
pubmed: 33150048
Prog Retin Eye Res. 2013 Jan;32:1-21
pubmed: 22995953
Invest Ophthalmol Vis Sci. 2019 Oct 1;60(13):4241-4248
pubmed: 31618760
Transl Vis Sci Technol. 2015 Nov 30;4(6):4
pubmed: 26644964
Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4646-51
pubmed: 20435603
Ophthalmology. 2009 Dec;116(12):2305-14.e1-2
pubmed: 19744726
Curr Opin Ophthalmol. 2002 Apr;13(2):77-84
pubmed: 11880719
Transl Vis Sci Technol. 2020 Mar 18;9(4):14
pubmed: 32818101
Ophthalmology. 2012 Apr;119(4):748-58
pubmed: 22218146
Am J Ophthalmol. 2021 Mar;223:119-128
pubmed: 32777374
Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30
pubmed: 12049575
Ophthalmology. 2017 Oct;124(10):1449-1456
pubmed: 28551166
J Glaucoma. 2018 Aug;27(8):657-664
pubmed: 29917000
Br J Ophthalmol. 2021 Jun;105(6):789-793
pubmed: 32699052
Ophthalmology. 2001 Oct;108(10):1812-8
pubmed: 11581054
Arch Ophthalmol. 2000 Sep;118(9):1187-94
pubmed: 10980763
Eye (Lond). 2009 Jun;23(6):1436-41
pubmed: 18806767
PLoS One. 2018 Jan 4;13(1):e0190621
pubmed: 29300765
Am J Ophthalmol. 2002 Aug;134(2):177-85
pubmed: 12140023
Ophthalmology. 1999 Nov;106(11):2144-53
pubmed: 10571351
Ophthalmology. 2011 Sep;118(9):1774-81
pubmed: 21550120
Curr Opin Ophthalmol. 2017 Mar;28(2):139-153
pubmed: 27898471
Am J Ophthalmol. 2021 Dec 21;237:71-82
pubmed: 34942111
J Glaucoma. 2020 Aug;29(8):671-680
pubmed: 32520765
Prog Retin Eye Res. 2007 Nov;26(6):688-710
pubmed: 17889587
J Glaucoma. 2019 May;28(5):368-374
pubmed: 30855415
Transl Vis Sci Technol. 2016 Apr 14;5(2):15
pubmed: 27134774
Eye (Lond). 2021 Nov;35(11):2973-2982
pubmed: 33414534